ZYBT - Wutah pendapatan triwulanan Zhengye Bio

Simbol lan logo merek Jilin Zhengye Biotechnology (ZYBT)

The QoQ revenue growth rate reflects sales dynamics, where -13.70 represents the latest metric reading. Zhengye Biotechnology (ZYBT) relies on its own vaccine production lines, outsourcing only logistics. Professional management effectively navigates regulatory barriers within the biotech sector. The company's innovative developments are critical for China's food security and receive state support.

ZYBT (Jilin Zhengye Biotechnology) riwayat Wutah dodolan triwulanan saka 08.01.2025 nganti 20.11.2026

Rincian metrik keuangan lan pasar Jilin Zhengye Biotechnology (ZYBT)

- rega saham lan prakiraan rega para ahli:
- data dhuwit lan arus kas:
Analisis dhasar perusahaan:ZYBT - Zhengye Biotechnology
Produk seri Zhengye Biotechnology Co., Ltd.

A qualitative asset assessment requires separating fundamental trends from market noise. This indicator measures quarterly sales expansion rates, allowing investors to identify business cycle inflection points. Analyzing the quarterly revenue growth rate helps determine the actual scaling speed of operational activities. For Zhengye Biotechnology (ZYBT), this trend directly reflects the demand for specialized livestock vaccines.